Appendix Table 10.

Effect on Primary Analyses of a Potentially Unmeasured Confounder^*

Outcome by Table	OR Associated With CAD (95% CI)
	Original Analysis With Potential Unmeasured Confounding	Sensitivity Analysis Accounting for Unmeasured Confounder
Table 1
Any breast cancer	1.04 (1.01–1.06)	1.00 (0.98–1.03)
Invasive breast cancer	1.00 (0.97–1.03)	0.96 (0.95–0.99)
Stage I invasive	1.06 (1.03–1.10)	1.03 (1.00–1.07)
Stages II–IV invasive	0.92 (0.87–0.96)	0.89 (0.85–0.93)
DCIS	1.17 (1.11–1.23)	1.15 (1.09–1.21)
Table 4
Smallest OR: Invasive size <1 cm (vs. ≥1 cm)	1.10 (1.04–1.16)	1.08 (1.02–1.14)
Largest OR: Invasive stage I or II (vs. III or IV)	1.27 (1.14–1.41)	1.25 (1.13–1.38)
Table 5
Smallest OR: Breast ultrasonography	1.08 (1.06–1.09)	1.05 (1.03–1.06)
Largest OR: Diagnostic mammography	1.28 (1.27–1.29)	1.25 (1.24–1.26)

CAD = computer-aided detection; DCIS = ductal carcinoma in situ; OR = odds ratio.

^*Sensitivity analyses assume a 10% relative imbalance in the prevalence of unmeasured increased breast density among women who receive screening mammography with CAD compared with women who receive screening without CAD.